BTAI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 35.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $5,803,034.11

BioXcel Therapeutics Insider Trading History Chart

BioXcel Therapeutics Share Price & Price History

^$2.53

▲ +0.04 (1.61%)

As of 09/29/2023 01:00 AM ET

Days: 30 | 90 | 365

Ben Stein FREE Report: How Americans Are RUINING Retirement

From Goldco | Ad

There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!

Request Your FREE Report Today!

BioXcel Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2023	Vimal Mehta	CEO	Sell	30,000	$21.54	$646,200.00	39,903
5/22/2023	Vimal Mehta	CEO	Sell	6,500	$25.79	$167,635.00	37,294
5/15/2023	Javier Rodriguez	Insider	Sell	1,785	$27.32	$48,766.20	4,350
5/15/2023	Richard I Steinhart	CFO	Sell	5,000	$27.17	$135,850.00	1,500
4/6/2023	Krishnan Nandabalan	Director	Sell	60,000	$17.32	$1,039,200.00
3/20/2023	Vimal Mehta	CEO	Sell	34,500	$18.32	$632,040.00	15,894
3/15/2023	Frank Yocca	Insider	Sell	985	$19.69	$19,394.65	9,496
3/15/2023	Richard I Steinhart	CFO	Sell	2,084	$19.50	$40,638.00	1,500
1/20/2023	Frank Yocca	Insider	Sell	50,000	$30.00	$1,500,000.00	8,397
1/5/2023	Krishnan Nandabalan	Director	Sell	25,889	$22.34	$578,360.26
12/16/2022	Vimal Mehta	CEO	Sell	30,000	$19.44	$583,200.00	9,957
11/10/2022	Krishnan Nandabalan	Director	Sell	27,450	$15.00	$411,750.00
6/25/2021	Vimal Mehta	CEO	Sell	473,250	$30.83	$14,590,297.50
2/17/2021	Vincent O'neill	Insider	Sell	25,000	$55.58	$1,389,500.00	15,000
1/25/2021	Frank Yocca	Insider	Sell	15,000	$48.39	$725,850.00	103,397
1/19/2021	Vincent O'neill	Insider	Sell	25,000	$49.47	$1,236,750.00	25,000

It’s finally here…

From ProTrading Research | Ad

Our analysts have finally finished the report we’ve all been waiting for.

The Top Five Ai Stocks that are part of the new AI Gold Rush happening in the world right now.

5 years from now, you just might wish you’d gotten in early on these stocks.

Click here to get the names of all 5 companies

SEC Filings (Institutional Ownership Changes) for BioXcel Therapeutics (NASDAQ:BTAI)

90.86% of BioXcel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioXcel Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2023	Alliancebernstein L.P.	35,880	$0.24M	0.0%	+49.5%	0.123%
8/15/2023	Wells Fargo & Company MN	77,381	$0.52M	0.0%	+62.5%	0.265%
8/15/2023	Knoll Capital Management LLC	30,000	$0.20M	0.2%	N/A	0.103%
8/15/2023	XTX Topco Ltd	16,509	$0.11M	0.0%	N/A	0.057%
8/15/2023	Goldman Sachs Group Inc.	144,046	$0.96M	0.0%	-12.0%	0.494%
8/15/2023	Point72 Asset Management L.P.	241,958	$1.61M	0.0%	N/A	0.830%
8/15/2023	Hudson Bay Capital Management LP	29,300	$0.20M	0.0%	N/A	0.100%
8/14/2023	Tower Research Capital LLC TRC	5,679	$38K	0.0%	+271.4%	0.019%
8/14/2023	State of Wisconsin Investment Board	28,623	$0.19M	0.0%	+19.8%	0.098%
8/14/2023	State Street Corp	2,072,199	$13.80M	0.0%	+17.7%	7.106%
8/14/2023	Nuveen Asset Management LLC	14,808	$99K	0.0%	-75.9%	0.051%
8/14/2023	Driehaus Capital Management LLC	22,220	$0.15M	0.0%	-94.3%	0.076%
8/14/2023	Thrivent Financial for Lutherans	10,000	$64K	0.0%	N/A	0.034%
8/11/2023	Credit Suisse AG	31,456	$0.21M	0.0%	+75.1%	0.108%
8/11/2023	BlackRock Inc.	1,389,229	$9.25M	0.0%	+1.4%	4.764%
8/11/2023	Geode Capital Management LLC	404,650	$2.70M	0.0%	+5.6%	1.388%
8/11/2023	E Fund Management Co. Ltd.	10,628	$71K	0.0%	N/A	0.036%
8/11/2023	JPMorgan Chase & Co.	21,440	$0.14M	0.0%	+24.0%	0.074%
8/11/2023	Northern Trust Corp	244,106	$1.63M	0.0%	+15.3%	0.837%
8/10/2023	Profund Advisors LLC	35,475	$0.24M	0.0%	+29.2%	0.122%
8/10/2023	US Bancorp DE	14,072	$94K	0.0%	+42,542.4%	0.048%
8/10/2023	Charles Schwab Investment Management Inc.	148,174	$0.99M	0.0%	+3.0%	0.508%
8/10/2023	Citigroup Inc.	60,062	$0.40M	0.0%	-49.5%	0.206%
8/9/2023	Dimensional Fund Advisors LP	37,668	$0.25M	0.0%	-38.7%	0.129%
8/9/2023	BNP Paribas Arbitrage SNC	69,994	$0.47M	0.0%	-38.5%	0.240%
8/9/2023	Swiss National Bank	44,200	$0.29M	0.0%	+4.5%	0.152%
8/3/2023	Barclays PLC	100,720	$0.67M	0.0%	+79.8%	0.344%
8/3/2023	Bank of New York Mellon Corp	113,121	$0.75M	0.0%	+46.7%	0.388%
7/25/2023	Raymond James & Associates	18,648	$0.12M	0.0%	+32.7%	0.064%
7/20/2023	DAVENPORT & Co LLC	59,705	$0.40M	0.0%	-25.6%	0.205%
7/19/2023	Artemis Investment Management LLP	895,048	$5.96M	0.1%	-8.8%	3.069%
7/14/2023	SeaCrest Wealth Management LLC	20,700	$0.14M	0.0%	+38.9%	0.071%
5/18/2023	JPMorgan Chase & Co.	17,291	$0.32M	0.0%	+49.1%	0.059%
5/18/2023	New York State Common Retirement Fund	10,885	$0.20M	0.0%	-5.9%	0.037%
5/16/2023	State Street Corp	1,760,683	$32.85M	0.0%	+377.7%	6.038%
5/16/2023	Geode Capital Management LLC	383,129	$7.15M	0.0%	+2.2%	1.314%
5/15/2023	Two Sigma Advisers LP	57,400	$1.07M	0.0%	+95.2%	0.198%
5/15/2023	Two Sigma Investments LP	217,991	$4.07M	0.0%	N/A	0.751%
5/15/2023	Deutsche Bank AG	27,665	$0.52M	0.0%	+14.5%	0.095%
5/12/2023	Renaissance Technologies LLC	94,000	$1.75M	0.0%	N/A	0.324%
5/12/2023	BlackRock Inc.	1,370,688	$25.58M	0.0%	-6.3%	4.725%
5/12/2023	BNP Paribas Arbitrage SNC	113,770	$2.12M	0.0%	+221.6%	0.392%
5/12/2023	AlphaCentric Advisors LLC	40,000	$0.75M	0.5%	-20.0%	0.138%
5/12/2023	Bank of America Corp DE	340,925	$6.36M	0.0%	+193.0%	1.175%
5/12/2023	UBS Group AG	160,289	$2.99M	0.0%	+15.1%	0.553%
5/12/2023	Dimensional Fund Advisors LP	61,432	$1.15M	0.0%	-11.4%	0.212%
5/12/2023	Wellington Management Group LLP	1,334,606	$24.90M	0.0%	N/A	4.601%
5/12/2023	SeaCrest Wealth Management LLC	14,907	$0.28M	0.0%	N/A	0.051%
5/12/2023	Charles Schwab Investment Management Inc.	143,893	$2.69M	0.0%	+0.4%	0.496%
5/12/2023	Profund Advisors LLC	27,462	$0.51M	0.0%	N/A	0.095%
5/11/2023	FMR LLC	4,276,693	$79.80M	0.0%	+1.7%	14.742%
5/11/2023	Rhumbline Advisers	33,490	$0.63M	0.0%	+8.5%	0.115%
5/11/2023	Citigroup Inc.	118,975	$2.22M	0.0%	+19,120.5%	0.410%
5/10/2023	Credit Suisse AG	17,963	$0.34M	0.0%	+28.5%	0.062%
5/10/2023	Tocqueville Asset Management L.P.	37,000	$0.69M	0.0%	-6.1%	0.128%
5/10/2023	Swiss National Bank	42,300	$0.79M	0.0%	-8.6%	0.146%
5/9/2023	Tower Research Capital LLC TRC	1,529	$29K	0.0%	+205.2%	0.005%
5/9/2023	Bank of New York Mellon Corp	77,132	$1.44M	0.0%	+7.2%	0.266%
5/8/2023	Federated Hermes Inc.	61,730	$1.15M	0.0%	N/A	0.213%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	12,103	$0.23M	0.0%	+8.2%	0.042%
5/5/2023	Truist Financial Corp	11,353	$0.21M	0.0%	-4.9%	0.039%
5/5/2023	Artemis Investment Management LLP	981,472	$18.28M	0.2%	-26.4%	3.383%
5/4/2023	Barclays PLC	56,023	$1.05M	0.0%	+990.8%	0.193%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	14,137	$0.26M	0.0%	N/A	0.049%
4/27/2023	DAVENPORT & Co LLC	80,295	$1.50M	0.0%	-48.9%	0.277%
4/21/2023	Capital Investment Advisory Services LLC	17,325	$0.32M	0.0%	N/A	0.060%
4/20/2023	Hennion & Walsh Asset Management Inc.	37,887	$0.71M	0.0%	-3.3%	0.131%
4/14/2023	Raymond James & Associates	14,052	$0.26M	0.0%	-11.8%	0.048%
4/13/2023	Allspring Global Investments Holdings LLC	49,311	$0.92M	0.0%	N/A	0.170%
2/21/2023	Northwestern Mutual Wealth Management Co.	1,740	$37K	0.0%	+411.8%	0.006%
2/17/2023	Truist Financial Corp	11,935	$0.26M	0.0%	-48.8%	0.043%
2/16/2023	Alliancebernstein L.P.	24,000	$0.52M	0.0%	+10.6%	0.086%
2/15/2023	State of Wisconsin Investment Board	56,636	$1.22M	0.0%	-18.3%	0.202%
2/15/2023	Legal & General Group Plc	9,678	$0.21M	0.0%	+7.5%	0.035%
2/15/2023	Morgan Stanley	124,997	$2.69M	0.0%	-50.9%	0.446%
2/15/2023	Alps Advisors Inc.	18,994	$0.41M	0.0%	+24.6%	0.068%
2/15/2023	Boothbay Fund Management LLC	50,450	$1.08M	0.0%	N/A	0.180%
2/14/2023	Driehaus Capital Management LLC	505,934	$10.87M	0.2%	N/A	1.806%
2/13/2023	Charles Schwab Investment Management Inc.	143,282	$3.08M	0.0%	+2.0%	0.511%
2/13/2023	Deutsche Bank AG	24,171	$0.52M	0.0%	-4.3%	0.086%
2/13/2023	Wells Fargo & Company MN	17,533	$0.38M	0.0%	-6.2%	0.063%
2/13/2023	Barclays PLC	5,136	$0.11M	0.0%	+533.3%	0.018%
2/13/2023	Geode Capital Management LLC	374,999	$8.05M	0.0%	+5.5%	1.338%
2/13/2023	JPMorgan Chase & Co.	11,595	$0.25M	0.0%	+9.5%	0.041%
2/10/2023	Bank of America Corp DE	116,361	$2.50M	0.0%	-5.7%	0.415%
2/10/2023	Sectoral Asset Management Inc.	61,156	$1.31M	0.3%	N/A	0.218%
2/9/2023	Tocqueville Asset Management L.P.	39,400	$0.85M	0.0%	+37.5%	0.141%
2/9/2023	Dimensional Fund Advisors LP	69,320	$1.49M	0.0%	-6.8%	0.247%
2/8/2023	Raymond James & Associates	15,929	$0.34M	0.0%	+32.8%	0.057%
2/8/2023	UBS Group AG	139,214	$2.99M	0.0%	-2.9%	0.497%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	11,182	$0.24M	0.0%	+50.0%	0.040%
1/25/2023	Artemis Investment Management LLP	1,333,691	$28.75M	0.3%	-3.0%	4.760%
1/20/2023	DAVENPORT & Co LLC	157,105	$3.38M	0.0%	+44.7%	0.561%
1/12/2023	Hennion & Walsh Asset Management Inc.	39,185	$0.84M	0.1%	+14.5%	0.140%
12/8/2022	Bank of New York Mellon Corp	65,219	$0.77M	0.0%	+7.3%	0.233%
11/16/2022	Jane Street Group LLC	12,666	$0.15M	0.0%	N/A	0.045%
11/16/2022	BNP Paribas Arbitrage SNC	53,971	$0.64M	0.0%	-14.3%	0.193%
11/15/2022	State Street Corp	369,672	$4.37M	0.0%	+1.2%	1.319%
11/15/2022	Two Sigma Advisers LP	64,700	$0.77M	0.0%	-34.8%	0.231%
11/15/2022	Two Sigma Investments LP	56,493	$0.67M	0.0%	-59.7%	0.202%

Data available starting January 2016

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $2.53

$2.51

$2.70

50 Day Range

MA: $5.03

$2.49

$10.95

52 Week Range

Now: $2.53

$2.48

$34.13

Volume

626,207 shs

Average Volume

901,274 shs

Market Capitalization

$74.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Who are the company insiders with the largest holdings of BioXcel Therapeutics?: BioXcel Therapeutics' top insider investors include:
Vimal Mehta (CEO)
Frank Yocca (Insider)
Javier Rodriguez (Insider)
Richard I Steinhart (CFO)
Krishnan Nandabalan (Director)
Learn More about top insider investors at BioXcel Therapeutics.